2Bhatia M. Quantitative analysis reveals expansion of hematopoietic repopulating ceils after short - term ex vivo culture [J ]. j Exp Med, 1997, 186(4) :619 - 624.
3Ishikaw a J, Maeda T, Kashiwagi H, et al. Successful second allo- geneic peripheral blood stem cell transplantation and donor lym- pbocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplanta- tion[J]. Bone Marrow Transplant, 2003, 31 ( 11 ) : 1 057 - 1 059.
2Quintas-Cardama A, Cortes J. Molecular biology of bcr-abll-posi- tive chronic myeloid leukemia [J]. Blood, 2009,113 ( 8 ) : 1619- 1630.
3Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinasc [ J ]. Cell, 2003,112 ( 6 ) : 859-871.
4Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib ( AMN107 ) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem ceils [ J ]. Leukemia, 2007,21 (6) :1267-1275.
5Krause DS, Lazarides K, yon Andrian UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leuke- mic stem cells [J]. Nat Med,2006, 12 (10) : 1175-1180.
7Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treat- ment options in chronic myeloid leukemia[ J]. Cancer,2007,109 ( 11 ) :2171-2181.
8Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular re- sponse with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia[ J]. J Clin Oncol, 2010,28 ( 8 ) : 1429-1435.
9Quintas-Cardama A, Cortes J. Therapeutic options against BCR- ABL1 T315I-positive chronic myelogenous leukemia [ J ]. Clin Cancer Res, 2008,14 ( 14 ) :4392-4399.
10Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells [J]. Blood, 2007, 110 ( 2 ) : 678-685.
